ArticleThe oncologist2023

Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.

Robert Motzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.